University of Birmingham

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

DDW Highlights: 21 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, key breakthroughs emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical… Read More

#Podcasts

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

This week in Drug Discovery (13 – 17 April) 

News round-up for 13 – 17 April by Bruno Quinney, Content Team at DDW.  This week, breakthroughs have emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical trial set up in the UK.  The top stories:    Novel therapy could slow tumour growth… Read More

#News

Arthritis
#Arthritis #University of Birmingham

Immunopeptide could delay inflammatory arthritis, study says 

An immunopeptide could help prevent or delay early-stage inflammatory arthritis, research shows.  Scientists investigating the naturally occurring immunopeptide PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) have shown reductions in arthritic joint swelling to a degree comparable to the current standard of care, reducing inflammatory changes that cause joint damage. … Read More

#News

University of Birmingham
#Autoimmune disease #Collaboration #Funding #Immune system #Osaka University #University of Birmingham #University of Oxford

Birmingham Uni and Nobel winner secure inflammation funding

Scientists and clinician-scientists at the University of Birmingham will lead a major research programme to transform the treatment of autoimmune diseases by halting chronic inflammation at its source.  Backed by a £3.83 ($5.1) million Wellcome Discovery Award, Birmingham researchers will join 2025 Nobel Prize winner Professor Shimon… Read More

#News

Ageing hands
#Age-related diseases (ARDs) #Ageing #Peptides #University of Birmingham

Natural peptide could protect against ‘inflammageing’

A naturally occurring peptide called ‘peptide inhibitor of trans-endothelial migration’ (PEPITEM) could potentially rejuvenate the immune response in older individuals, according to a new study. The authors believe the peptide could protect against ‘inflammageing’, widely believed to be the root cause of many age-related diseases. Read More

#News #Trending News

Knee x-ray
#Bone disease #Peptides #Preclinical investigations #University of Birmingham

Peptide shows promise as therapeutic for bone loss disorders

Researchers have shown that a naturally occurring peptide holds promise as a new therapeutic for bone loss disorders and could have advantages over existing drugs. PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) was first identified in 2015 by University of Birmingham researchers. The latest research… Read More

#News

University of Birmingham
#Academic #Drug discovery #Funding #Investment #Start-ups #University of Birmingham

Birmingham, UK, Drug Discovery Hub created

The Birmingham Drug Discovery Hub (BDDH) has been set up to help University of Birmingham researchers to overcome the ‘valley of death’, where projects fail due to the funding gap between original research and commercial investment. The hub has attracted more than £4 ($4.9) million in… Read More

#News #Start-up Zone

Examining a sample under the microscope
#Antibody Fragments #Cardiovascular disease #Nanobodies #Thrombosis #University of Birmingham

Novel nanobody technology boosts thrombosis research

Researchers from the Institute of Cardiovascular Sciences at the University of Birmingham, UK, have produced the first binding molecules (ligands) of defined composition to make platelets clump together in a predictable way. The research team, led by Professor Steve Watson and Dr Eleyna Martin, developed antibody… Read More

#News

Idiopathic intracranial hypertension
#Brain #Neuroinflammation #Neurology #Phase II trial #Type 2 diabetes #University of Birmingham

Type 2 diabetes drug could treat blinding IIH headaches

Patients with ‘blinding’ headaches known as idiopathic intracranial hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The study was led by a team of neurologists from the University of Birmingham and University Hospitals Birmingham, and… Read More

#News #Trending News

#AstraZeneca #Spinal cord injury #University of Birmingham

Researchers identify possible treatment for spinal cord injury 

An existing drug could help reduce spinal cord injury damage, scientists at the University of Birmingham have discovered.   A team of scientists from the University of Birmingham found that an enzyme inhibitor developed by AstraZeneca can significantly reduce ‘secondary damage’ caused by the body’s response to spinal… Read More

#News

#AstraZeneca #GSK #Malaria #University of Birmingham

This week in drug discovery (25-29 April)  

News round-up by DDW’s Reece Armstrong for 25-29 April     Q1 earnings, formulations to tackle blindness, liver cancer therapies and opportunities for malaria treatments are some of the themes of this week’s news round-up.  What’s behind GSK’s strong Q1 earnings?  DDW Deputy… Read More

#News

#Ocular diseases #Spinout #University of Birmingham

New spinout to tackle blindness with novel gel  

A new spinout has launched from the University of Birmingham targeting treatments for the leading causes of preventable blindness.  Healome Therapeutics is developing a platform that delivers a ‘pro-healing’ microenvironment for causes of preventable blindness. The company’s platform will be targeted at ocular surface diseases, which are… Read More

#News